NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), today reported it has closed its previously announced registered direct equity offering of common stock and warrants. The Company received net proceeds of approximately $3.5 million.
